Ripretinib
- Generic Name
- Ripretinib
- Brand Names
- Qinlock
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21BrFN5O2
- CAS Number
- 1442472-39-0
- Unique Ingredient Identifier
- 9XW757O13D
- Background
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
...
- Indication
Ripretinib is indicated to treat adults diagnosed with advanced gastrointestinal stromal tumor (GIST) who have had prior therapy with at least 3 kinase inhibitors, including with imatinib.
- Associated Conditions
- Advanced Gastrointestinal Stromal Tumor (GIST)
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath